Fosun Pharma and Teva Announce Strategic Collaboration to Co-Develop Novel Anti-PD1-IL2 ATTENUKINE™ Therapy TEV-56278 for Cancer Immunotherapy

Stock trading depends onGolden Qilin Analyst Report, authoritative, professional, timely, comprehensive, help you explore potential thematic opportunities!

June 16,Fosun PharmaceuticalJointly announced with Teva Pharmaceutical Industries Ltd. ("Teva") that both parties, through their respective subsidiaries, have reached a strategic cooperation agreement for the development of the investigational drug anti-PD1-IL2 ATTENUKINE™ therapy TEV-56278. According to the agreement, to accelerate clinical data development, Fosun Pharmaceutical will obtain the exclusive rights for the development, production, and commercialization of TEV-56278 in China (including Hong Kong, Macao, and Taiwan regions) as well as in certain Southeast Asian countries. Teva retains the rights for the development, production, and commercialization of TEV-56278 in other global regions.